GT Biopharma Inc. (GTBP) financial statements (2021 and earlier)

Company profile

Business Address 9350 WILSHIRE BLVD.
BEVERLY HILLS, CA 90212
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 00100
Cash and cash equivalents 00100
Prepaid expense 00 00
Total current assets: 00100
Noncurrent Assets
Property, plant and equipment  0000
Intangible assets, net (including goodwill), including:  25254  
Other undisclosed intangible assets, net (including goodwill)  25254  
Deposits noncurrent assets 000  
Other undisclosed noncurrent assets 0    
Total noncurrent assets: 02525400
TOTAL ASSETS: 02525400
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 63368
Accounts payable 22321
Accrued liabilities 21004
Interest and dividends payable 2  42
Debt 1311 11
Deferred rent credit  0
Due to related parties  0   
Other undisclosed current liabilities 0001253
Total current liabilities: 201431961
Noncurrent Liabilities
Long-term debt and lease obligation     1
Long-term debt, excluding current maturities     1
Total noncurrent liabilities:     1
Total liabilities: 201431962
Stockholders' equity
Stockholders' equity attributable to parent, including: (19)11252(19)(62)
Common stock 00000
Additional paid in capital 54854052010684
Accumulated deficit (567)(529)(268)(125)(146)
Other undisclosed stockholders' equity attributable to parent (0)(0)(0)(0)(0)
Total stockholders' equity: (19)11252(19)(62)
TOTAL LIABILITIES AND EQUITY: 02525400

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:     0
Operating expenses (16)(250)(136)(9)(9)
Operating loss: (16)(250)(136)(9)(9)
Nonoperating income (expense) (23)(9)(8)19(24)
Investment income, nonoperating (5)(229)   
Interest and debt expense (2)(9)(9)(7)(17)
Income (loss) from continuing operations before equity method investments, income taxes: (41)(268)(152)3(50)
Other undisclosed income from continuing operations before income taxes 299717
Net income (loss) available to common stockholders, diluted: (39)(259)(143)10(33)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss): (39)(259)(143)10(33)
Comprehensive income (loss), net of tax, attributable to parent: (39)(259)(143)10(33)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: